Dhiren has over 15 years of asset and fund management experience and has been involved in fund raising and in strategic advisory role with startups ranging from applied technology, healthcare, engineering and education sectors. He started his career as an engineer manufacturing electric locomotives, went on to do financial engineering with high-risk high-yield assets and has now been managing Merlin for the last 6 years. He holds an MBA from the Asian Institute of Management and Stockholm School of Economics, Bachelor of Electrical Engineering degree and the Chartered Alternate Investment Analyst (CAIA).
Prof Cognard is the Chairman of the Department of Diagnostics and Therapeutic Neuroradiology Hospital of Purpan and Hospital of Rangueil since Dec. 2002. He is also the Professor of Radiology, University of Toulouse since Sept. 1999 and was also the invited professor to the University of Montreal in 2008. Previously he was a Consultant in the Department of Neuroradiology, Rothschild Ophthalmological Foundation (Prof. J. Moret), from 1995 to 1997. He has earlier been the President of the Annual Congress of the French Society of Neuroradiology (SFNR). He has also held the positions of President , General Secretary of the Annual Congress of the ESMINT, Nice from 2009 to 2014. He has over 150 publications in scientific journals, 22 didactic articles and 6 book chapters.
Kumar is a Chemical Engineer by background and a Doctorate in Pharmaceutical science from Purdue University. Before being Senior Research Fellow at Nanyang Technological University -Singapore, he was a Research Scientist at Mercy Medical, Springfield USA, where he was a key member of product development – bio adhesives and drug delivering contact lenses, where he has published patents in his name. Kumar was earlier a Post Doc Research Fellow in Orthopaedic Biomaterials and tissue Engineering lab in Center for Biomedic Systems in Charlotte, USA, where he served as a project lead to engineer the drug delivery for synergistic delivery of antibiotics and bone morphogenetic protein for treatment of osteomyelitis. He also lead a project in collaboration with Carolina Medical Center (CMC, charlotte, USA) in designing a novel controlled release drug delivery system in treatment of liver cancer. Served as a co-principal investigator for R-15 proposal submitted to National Institute of Health (NIH, USA). Earlier he was with Vertex Pharma, Masschusetts in Formulation development and did an internship with Bristol Myers Squibb New York. He has about 8 publications/book chapters and has presented his work in 6 conferences.
Orla has previously work with Abbott Vascular for about 6 years in Quality & Regulatory affairs and earlier at Boston Scientific ( 3years) and Mayo Institute of technology ( 2 years). Orla is a Director of Regulatory affairs at Creganna Medical, one the world’s biggest medical device design and manufacturing company, specially in Catheters. She has helped them obtain multiple CE approvals, FDA 510k clearances, Canadian, Australian, Japanese and Chinese approvals for a variety of classification of medical devices, registered medical devices to allow commercialization in a variety of countries outside of these jurisdictions, produced Post Market Surveillance reports, Generated Clinical Evaluation reports, Delivered complaint reportability assessments for every complaint received on legally manufactured products and produced and submitted the medical device reports for the various regulatory agencies as required. Previously she was with Veryan Medical, a company focused on peripheral stenting products, where she provided strategic Regulatory & Clinical guidance , pre-IDE submissions and CE submissions. She currently also advices Vysera Biomedical, a company which makes non-invasive devices in GI space. She is member of the Senior Management team and works on their Regulatory strategy, CE submissions and other Clinical Strategy. She is also an Academic Associate to the College of Business at the University of Limerick and a Masters Thesis Supervisor there.
With 24 years of experience and over 65 issued U.S. Patents to his name, J Christopher Flaherty is a leading inventor in the field of medical device technology. Mr. Flaherty's patents and applications span a broad range of medical technologies covering products in areas of Cardiovascular, Drug Delivery, Neurological, Orthopedic, Gynecological, Limb movement and Prosthetic, Clinician Controlled Robots; and Medical Energy Delivery systems. Through his years managing the patent portfolios of medical device companies now owned by such industry leaders as Medtronics and Pfizer, Mr. Flaherty developed a sophisticated software program to expedite patent filings and manage intellectual property development. He has managed pre-clinical research efforts, has been responsible for FDA and other regulatory approvals, has overseen the performance of large-scale animal tests, and has led teams through European and American clinical trials. Mr. Flaherty has been an invited speaker at the United States Patent and Trademark Office, presenting new technologies. He earned a B.S. in Aeronautical and Electrical Engineering from MIT in 1985, where he won the Luis de Florez award for inventiveness.